Second-Line Antiretroviral Therapy for Children Living with HIV in Africa.

Name: Αlpha¹ Rigor Record — Second-Line Antiretroviral Therapy for Children Living with HIV in Africa.
Item: Second-Line Antiretroviral Therapy for Children Living with HIV in Africa.
Rating: 59
Author: Αlpha¹

Musiime V, Bwakura-Dangarembizi M, Szubert AJ, Mumbiro V, Mujuru HA, Kityo CM, Lugemwa A, Doerholt K, Chabala C, Makumbi S, Mulenga V, McIlleron H, Burger D, Natukunda E, Shakeshaft C, Linda KJ, Nathoo K, Monkiewicz L, Yawe I, Kapasa M, Nyathi M, Lungu J, Nduna B, Ndebele W, South A, Mwamabazi M, Musoro G, Griffiths A, Zyambo K, Nazzinda R, Zimba K, Zhang Y, Walker S, Turkova A, Walker AS, Bamford A, Gibb DM, CHAPAS-4 Trial Team

Paper source

Read full text (PMC)

Embed this Rigor badge

Αlpha¹ Rigor Review — 3★ (Adequate), 0 critical, 5 high issues for “Second-Line Antiretroviral Therapy for Children Living with HIV in Africa.”

Links back to this Rigor Record.

Αlpha¹ Editorial

This rigor review was examined and confirmed by Αlpha¹ Editorial · August 10, 2026

Αlpha¹ Rigor Review

Rigor Reviewed

3 / 5

Adequate — real issues to address

Interventional Study

Critical

High-priority

How this rating was calculated▸

Started at 5★ — deductions

ClaimsEfficacy rests on an unvalidated surrogate endpoint−0.5★
ClaimsTreatment effect not shown to be clinically meaningful−0.5★
ReportingData & code availability not met−0.5★
ReportingEthical approvals partially met−0.25★
ReportingKey resources partially met−0.25★

Model-reported confidence: moderateReviewer agreement: highEngine: 7.29.0Source: full text

Not verified in this report

The numeric-impossibility checks (GRIM/GRIMMER/DEBIT/SPRITE) did not run on this paper: the pass that reads its reported means did not complete. No reported mean was checked for arithmetic impossibility.
No data or code availability links were detected to verify.

Problems surfaced5 types

Overstated conclusions2

Conclusions that reach past what the paper's own results support — including a significance claim that no longer holds when the statistic is recomputed, and efficacy resting on an unvalidated surrogate endpoint.

Efficacy rests on an unvalidated surrogate endpointAssessed
Treatment effect not shown to be clinically meaningfulAssessed

Reporting gaps3

Required detail the manuscript never states — study design, biological variables, ethics approval and consent, key resources, statistical reporting, data and code availability, and overall transparency.

Data and code not sharedAssessed
Ethics/consent reporting incompleteAssessed
Key resources under-identified (antibodies, cell lines, RRIDs)Assessed

This Αlpha¹ Rigor Review uses AI Rigor Reviewers trained on a curated corpus of high-fidelity and retracted papers, with expert supervision and curation. It can still make mistakes; verify each finding against the source before relying on it.

This paper reports a well-conducted factorial RCT with strong design, statistical analysis, and reporting transparency. However, two notable gaps exist: no data availability statement and no explicit regulatory compliance framework. The key resources dimension is borderline due to deferred dosing details.

Both independent reviewer runs converged on most dimensions; the only divergence was on key resources, resolved to warn because anchor-drug dosing is deferred to the protocol. The statistics verification component checked 7 tests and found all consistent; the citation component found no retracted or unresolved references. The copyedit pass identified minor typographical and formatting issues.

9 major claims checked against the paper's own evidence: all adequately supported.

Premise concern: surrogate not validated for clinical benefit; effect size not shown to be clinically meaningful.

Recomputed 7 tests: 7 consistent, 0 inconsistent; 7 via agent-written checks.

Reporting

Eight Dimensions5 pass · 2 warn · 1 fail

Prior work is cited extensively (ODYSSEY, NADIA, DAWNING, VISEND, adult TAF trials) with strengths and weaknesses acknowledged (e.g., LPV/r unpalatability, DRV/r cost, TAF bone/renal safety rationale). The premise that backbone and anchor drug choice is unresolved is explicitly stated and links directly to the trial objectives. Limitations of the evidence base and of the trial itself are discussed in the Discussion.

Sub-criteria

prior work citedADEQUATE

premise rationaleADEQUATE

limitations addressedADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

The paper establishes a clear scientific gap — limited paediatric second-line ART options and minimal TAF data in African children — and builds a logical rationale for the factorial comparison.

Evidence

direct quote[Background, paragraph 1]

“There are minimal data on TAF in African children; the first paediatric pharmacokinetic data showed tenofovir concentrations equivalent to those safe and effective in adults.”